Execution on AI Deals, Margin Recovery Under Watch

Hexaware reports Q1 FY-2027 on July 29, after a softer prior quarter (Q1 CY26, ended Mar 2026) that saw constant-currency revenue growth slow to 3.2% YoY and EBIT margins compress 133 bps to 13.0%. The Street expects a muted first half (management guided 13–14% full-year EBIT, with recovery back-weighted to H2), but will scrutinize two things: (1) whether the company is converting recent AI deal wins into meaningful revenue, and (2) whether Q1 margins point to a trajectory back to historical 14%+ levels by year-end.

A strong Q1 print would show revenue hitting the top of guidance (7.6%+ YoY, INR terms), EBIT margin stabilizing near 13% (not re-compressing), and commentary affirming that AI deal wins are ramping into production and the margin glide path is intact. A weak print would be low single-digit constant-currency growth, EBIT margin below 12.5% with no credible commentary on H2 recovery, or a cut to full-year guidance. Guidance holds are not priced in; the market expects confidence reaffirmed.

Hexaware has guided 7.6% revenue growth for CY26 and EBIT margins of 13–14%, expecting the second half to be higher-margin than H1. Q1 CY26 (ended Mar 26) delivered 3.2% constant-currency growth and 13.0% EBIT—not a miss, but a signal that the top line faces headwinds (client modernization cycles still soft; deal velocity lumpier than prior cycles). Management attributed the margin pressure to onshore wage inflation and project-mix effects, implying H2 will be better as large deals ramp. The Street is tracking whether this plays out or whether the full-year guide needs downside revision.

Hexaware enters Q1 FY-2027 at a valuation inflection: the stock has halved from ATH (₹807 → ₹552), and the consensus expects margin recovery and AI-led deal acceleration to re-rate it higher. The company has three macro tailwinds (AI transformation spending, hyperscaler growth, platform expansion) and one headwind (cautious client spending in first half = lower deal momentum). Management's commentary on H2 margin recovery and AI deal velocity will be parsed line-by-line; any hint of conservatism or guide cut could trigger a retest of recent lows. Conversely, a reaffirmation of 13–14% EBIT + evidence of AI deal wins ramping into production would support the analyst bull case and the 57% upside to consensus target.

1. Margin trajectory & commentary: Is EBIT margin ≥ 12.8%? Is management confident in the H2 recovery narrative, or are there signs of delays? Any guidance revision (up or down)? 2. Large-deal traction: Customer count >$10M (expect 35–36 vs. 34 prior)? Deal pipeline and win rates in AI/transformation—is the recent leadership churn translating to pipeline momentum? 3. Capital allocation + capex intensity: How much cash is the UK investment consuming? Is organic free cash flow (the company's historic strength, 125%+ LTM OCF-to-PAT) holding up amid M&A and expansion spend?